(PHILADELPHIA) - NeutroSpec, a new imaging agent approved by the Food and Drug Administration for detecting certain difficult-to-diagnose cases of appendicitis quickly and accurately, is based on a monoclonal antibody called SSEA1 discovered at The Wistar Institute. Developed further by Palatin Technologies Inc., located in Cranbury, NJ, with assistance from Thomas Jefferson University, also in Philadelphia, NeutroSpec will be marketed by Mallinckrodt Imaging, a St. Louis-based unit of Tyco Healthcare, a global medical products company headquartered in Bermuda.
"The success of NeutroSpec reflects the Philadelphia area's enormous strengths in biomedical research and development," says Russel E. Kaufman, M.D., president and CEO of The Wistar Institute. "Contributions from academic scientists at two leading Philadelphia research institutions helped an early-stage biotechnology company in the region and its international corporate partners bring to the clinic an important advance in physicians' ability to diagnose hidden infections."
The Wistar antibody, labeled with radioactive technetium to create NeutroSpec, binds selectively to the CD15 receptor on neutrophils, a type of white blood cell that travels through the body to sites of infection. When injected into the blood, NeutroSpec binds to neutrophils battling an infection, allowing physicians to detect the infection with a gamma camera, a common piece of equipment in hospital nuclear medicine departments.
The FDA approved NeutroSpec for use in patients five years of age or older with equivocal symptoms of appendicitis. It is estimated that about half of the 700,000 patients in the United States with suspected appendicitis each year lack distinctive symptoms, such as pain and tenderness in the right lower abdomen, fever, nausea, and an elevated white blood cell count.
NeutroSpec enables physicians to rapidly diagnose appendicitis in cases without straightforward symptoms, eliminating tPage: 1 2 Related biology news :1
Contact: Franklin Hoke
The Wistar Institute
. Experimental hantavirus vaccine elicits strong antibody response in primates2
. Towards an AIDS vaccine: unusual antibody that targets HIV described by scientists at TSRI3
. Structure of HIV-neutralizing antibody solved4
. New antibody library speeds search for new detection tools5
. Wistar-developed antibody shows promise against brain tumors in Drexel trial6
. FDA approves new treatment, Campath , humanized monoclonal antibody, for patients with B-cell chronic lymphocytic leukemia7
. Rockefeller University researchers discover immune-cell mechanism that boosts therapeutic antibody potency8
. Abgenix to become sole owner of Xenomouse fully human antibody technology9
. Abgenix and CuraGen establish large-scale drug development alliance, companies to develop genomics-based human antibody drugs10
. Human Genome Sciences and Abgenix enter a broad collaboration to create fully human antibody
. Abgenix and Chiron enter Xenomouse Technology Collaboration, targets antibody products for autoimmune
disease and cancer